Patent · US Active

Use of low dose IL-2 for treating autoimmune-related or inflammatory disorders

US11559566B2 · kind B2 · utility

0Cited by

4References

16Claims

0Family size

Assignees

INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) · FR
ASSISTANCE PUBLIQUE—HÔPITAUX DE PARIS (APHP) · FR
Sorbonne Universite · FR

Inventors

David Klatzmann · Paris, FR
David Saadoun · Neuilly-sur-Seine, FR
Patrice Cacoub · Dozulé, FR
Michèle Rosenzwajg · Paris, FR
Eliane Piaggio · Paris, FR
Gilbert Bensimon · Villejuif, FR
Claude Bernard · Malakoff, FR

Key dates

Filing date	Jul 10, 2020
Grant date	Jan 24, 2023
Priority date	—
Expiry date	Apr 20, 2041

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P37/08
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to novel therapies for treating autoimmune and inflammatory diseases. More specifically, the present invention relates to a use of low dose interleukin-2 for the treatment of type I diabetes and other autoimmune and/or inflammatory diseases.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.